305 related articles for article (PubMed ID: 33576497)
21. Are serious ophthalmic adverse events on dupilumab treatment for atopic dermatitis dose related?
Mastorino L; Ortoncelli M; Avallone G; Quaglino P; Ribero S
Int J Dermatol; 2022 Oct; 61(10):e370-e372. PubMed ID: 34865213
[No Abstract] [Full Text] [Related]
22. [Dupilumab-related blepharoconjunctivitis: Recommendations of the CEDRE group. Atopic dermatitis, conjunctivitis and dupilumab: Which management approach?].
Doan S; Arnould L; Febvay C; Fournié P; Gueudry J; Labalette P; Ouilhon C; Tran TH; Vabres B; Barbarot S; Bouaziz JD; Du-Thanh A; Jachiet M; Seneschal J; Soria A; Staumont-Sallé D; Baudouin C; Mortemousque B
J Fr Ophtalmol; 2022 Mar; 45(3):277-287. PubMed ID: 35078645
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
[TBL] [Abstract][Full Text] [Related]
24. Pathomechanism of dupilumab-associated inflammatory eye symptoms.
Wohlrab J; Werfel T; Wollenberg A
J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e435-e436. PubMed ID: 31220376
[No Abstract] [Full Text] [Related]
25. Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis.
Voorberg AN; den Dunnen WFA; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e64-e66. PubMed ID: 31465590
[No Abstract] [Full Text] [Related]
26. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
[TBL] [Abstract][Full Text] [Related]
27. Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis.
Fukuda K; Ishida W; Kishimoto T; Fukushima A
Allergol Int; 2019 Jul; 68(3):383-384. PubMed ID: 30718036
[No Abstract] [Full Text] [Related]
28. Improvement of dupilumab-associated conjunctivitis after switching to upadacitinib in a patient with atopic dermatitis.
Hayama K; Fujita H
Dermatol Ther; 2022 Jul; 35(7):e15575. PubMed ID: 35536445
[No Abstract] [Full Text] [Related]
29. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
Ariëns LFM; van der Schaft J; Spekhorst LS; Bakker DS; Romeijn GLE; Kouwenhoven TA; Kamsteeg M; Voorberg AN; Oosting AJ; de Ridder I; Sloeserwij A; Haeck I; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
J Am Acad Dermatol; 2021 Apr; 84(4):1000-1009. PubMed ID: 32946967
[TBL] [Abstract][Full Text] [Related]
30. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
[TBL] [Abstract][Full Text] [Related]
31. Analysis of cytokines in tear fluid from atopic dermatitis patients with dupilumab-associated ocular adverse events.
Vuillemey L; Febvay C; Puzenat E; Bellanger AP; Chague C; Puyraveau M; Delbosc B; Gauthier AS; Aubin F
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):e195-e197. PubMed ID: 34626023
[No Abstract] [Full Text] [Related]
32. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
Treister AD; Kraff-Cooper C; Lio PA
JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
[TBL] [Abstract][Full Text] [Related]
33. Dupilumab-Induced Follicular Conjunctivitis.
Shen E; Xie K; Jwo K; Smith J; Mosaed S
Ocul Immunol Inflamm; 2019; 27(8):1339-1341. PubMed ID: 30335586
[No Abstract] [Full Text] [Related]
34. Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients.
Costedoat I; Wallaert M; Gaultier A; Vasseur R; Vanhaecke C; Viguier M; Cordelette C; Denoyer A; Ferrier le Bouëdec MC; Coutu A; Lamiaux M; Tran THC; Lacour JP; Elmaleh V; Tetart F; Gueudry J; Tauber M; Giordano-Labadie F; Cassagne M; Nosbaum A; Ouilhon C; Jachiet M; Tadayoni R; Dezoteux F; Staumont-Salle D; Bouleau J; Labalette P; Doan S; Soria A; Mortemousque B; Seneschal J; Barbarot S;
J Eur Acad Dermatol Venereol; 2023 May; 37(5):1056-1063. PubMed ID: 36732052
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Simpson EL; Paller AS; Siegfried EC; Boguniewicz M; Sher L; Gooderham MJ; Beck LA; Guttman-Yassky E; Pariser D; Blauvelt A; Weisman J; Lockshin B; Hultsch T; Zhang Q; Kamal MA; Davis JD; Akinlade B; Staudinger H; Hamilton JD; Graham NMH; Pirozzi G; Gadkari A; Eckert L; Stahl N; Yancopoulos GD; Ruddy M; Bansal A
JAMA Dermatol; 2020 Jan; 156(1):44-56. PubMed ID: 31693077
[TBL] [Abstract][Full Text] [Related]
36. Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab.
Ferrucci S; Tavecchio S; Berti E; Angileri L
Clin Exp Dermatol; 2020 Jul; 45(5):625-626. PubMed ID: 32112580
[No Abstract] [Full Text] [Related]
37. Prophylactic use of diquafosol eye drops for dupilumab-associated conjunctivitis in patients with severe atopic dermatitis: An open-label prospective study.
Shin K; Lee JS; Jeon H; Lee GW; Shin JO; Roh D; Kim Y; Won SH; Lee J; Kim HS; Kim BS; Kim MB; Ko HC
Allergy; 2024 Mar; 79(3):746-748. PubMed ID: 37937411
[No Abstract] [Full Text] [Related]
38. Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic.
Hansel K; Patruno C; Antonelli E; Dal Bello G; Napolitano M; Fabbrocini G; Grieco T; Pellacani G; Fargnoli MC; Esposito M; Piras V; Zucca M; Girolomoni G; Stingeni L
Clin Exp Dermatol; 2022 Jan; 47(1):165-167. PubMed ID: 34309892
[No Abstract] [Full Text] [Related]
39. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment.
Wollenberg A; Ariens L; Thurau S; van Luijk C; Seegräber M; de Bruin-Weller M
J Allergy Clin Immunol Pract; 2018; 6(5):1778-1780.e1. PubMed ID: 29432961
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
